Updates ·
Health notices · Sunday 27 September
3 notices from the agencies today, in plain words, each with the original linked.
FDA approved Inluriyo for certain ER-positive metastatic breast cancers
FDA · Approval
If you have advanced or metastatic breast cancer that is ER-positive and HER2-negative, and your tumor has an ESR1 mutation, the FDA has approved Inluriyo. It’s for cancer that has grown despite at least one prior line of endocrine therapy.
Endocrine therapy means treatment that changes hormones to slow hormone-driven breast cancer. Inluriyo works as an estrogen receptor antagonist, blocking the estrogen receptor so the cancer can’t use estrogen the same way.
This approval may give your clinician another treatment option if your disease progressed after endocrine therapy.
FDA approves epinephrine for septic shock–related hypotension
FDA · Approval
If you are an adult with low blood pressure caused by septic shock, the US Food and Drug Administration has approved Epinephrine.
This medicine is meant to increase mean arterial blood pressure during septic shock–related hypotension.
If this applies to you, ask your clinician whether Epinephrine is appropriate for your situation.
What to do
- Use Epinephrine as indicated for adult hypotension associated with septic shock.
FDA approves calcium gluconate in sodium chloride injection
FDA · Approval
If you have acute symptomatic hypocalcemia, the US FDA says this Calcium Gluconate in Sodium Chloride Injection is indicated for treatment in pediatric and adult patients.
Hypocalcemia means you have too little calcium in your blood; “acute symptomatic” means it is sudden and causing symptoms.